Role of PTGIS: PTGIS expression is elevated in early liver fibrosis but declines in chronic stages, correlating with reduced anti-inflammatory signaling .
Experimental Use: Overexpression of PTGIS in HSCs inhibits fibrosis markers (e.g., α-SMA, COL1A1) and promotes apoptosis, suggesting therapeutic potential . FITC-conjugated antibodies could track PTGIS localization in activated HSCs .
Prostacyclin Signaling: PTGIS-derived PGI2 suppresses T-cell proliferation and modulates macrophage polarization. In cancer-associated fibroblasts (CAFs), PTGIS expression is linked to PGI2-mediated anti-inflammatory effects .
Antibody Utility: FITC-conjugated PTGIS antibodies help identify PTGIS-expressing CAFs in tumor microenvironments and assess their interaction with PTGIR-expressing macrophages .
PTGIS in FDCs: Human FDCs express PTGIS, producing PGI2 to regulate T-cell survival and proliferation. The 3C8 monoclonal antibody (later identified as anti-PGIS) was pivotal in demonstrating this role .
Diagnostic Potential: FITC-conjugated antibodies could enable fluorescence-based detection of FDCs in lymphoid tissues .
4. Data Tables: Antibody Specificity and Performance
Table 1: PTGIS Antibody Specificity